Latest Januvia news
FDA: Common Diabetes Drug Januvia May Contain Traces of Carcinogen
posted August 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA: Common Diabetes Drug Januvia May Contain Traces of Carcinogen
posted August 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
Sitagliptin Stimulates Distal Tubular Natriuresis in T2DM
posted June 9th
by modernClinician Editorial Team
by modernClinician Editorial Team
For patients with type 2 diabetes, the dipeptidyl peptidase-4 inhibitor sitagliptin stimulates distal tubular natriuresis, according to a study published online May 26 in Diabetes Care.
Sitagliptin Has Neutral CV Risk Effect in Elderly With T2DM, CVD
posted January 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes, according to a study published online Jan. 5 in Diabetes Care.
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Study IDs Dementia Risk Factors in Those Older Than 90 Years 
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD 
Type 2 Diabetes Linked to Worse Menopausal Symptoms 
Sitagliptin Not Linked to Higher Fracture Risk in Diabetes 
Metformin, Sitagliptin Prolong Normoglycemia Remission in DKA 
Vildagliptin, Sitagliptin Have Similar Effects on Incretin Monthly Specialist Briefings
Stay Connected
